P.1.e.010 Peroxiredoxin-1 (PRDX-1) and Peroxiredoxin-3 (PRDX-3) as Indicators of Sickness Behaviour in Patients with Varying Levels of Depression Severity E.A. Ogłodek (1), M.J. Just (2), D.M. Moś (3), K. Just (1),A. Grzesińska (1), M. Frąszczak(1),A.Araszkiewicz (1)

(1) Department of Psychiatry, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Bydgoszcz, Poland (2) Department of General and Endocrine Surgery, Municipal Hospital in Piekary Śląskie, Poland (3) Health Care Centre Euro-Med Bytom, Poland

BACKGROUND is the condition that occurs from the imbalance between (ROS) and systems. Considering that the brain is particularly vulnerable to oxidative stress as a result of the relatively low levels of , high levels of polyunsaturated fatty acids and increased need of oxygen, there is an increase awareness regarding the importance of oxidative stress in most of the neuropsychiatric disorders. Peroxiredoxins (Peroxiredoxin-1, Peroxiredoxin-3) are a family of ubiquitous antioxidant known to be involved in sensing and detoxifying (H2O2) and other reactive oxygen species [1]. Peroxiredoxins are a family of antioxidant proteins which has been shown to participate in a number of vital biological processes such as antioxidant defence, signalling apoptosis control and kinase modulation. Numerous studies have demonstrated that peroxiredoxins call protect cells against a variety of nitrosative stress [2, 3].

AIM OF THE STUDY The aim of the study was to compare the concentrations of Peroxiredoxin-1 (PRDX-1) and Peroxiredoxin-3 (PRDX-3) with regard to gender and varying levels of depression severity. METHODS The study comprised 160 individuals (40 controls and 40 patients at each out of three levels of depression severity). Each group of 40 subjects included 20 females and 20 males. The group of depressed patients included subjects diagnosed with depressive episodes classified as mild, moderate and severe. A standardized classification system called the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) was utilized to diagnose depressive disorder. In order to measure depression severity, the psychometric properties of the Beck Depression Inventory (BDI-II) developed by Aaron T. Beck were examined. Serum Peroxiredoxin-1 (PRDX-1) and Peroxiredoxin-3 (PRDX-3) levels were measured by the -linked immunosorbent assay (ELISA). RESULTS With regard to Peroxiredoxin-1, statistically significant differences were observed between males (2848.93±63.52) and females (3333.66±115.48) from the control group. Serum PRDX-1 concentrations were substantially higher in females than males. The lowest PRDX-1 concentration was reported in females with severe depression (2232.35±43.65), slightly higher in females with moderate depression (2414.47±84.89), and most elevated in females with mild depression (2879.26±23.54). The differences that were found between the groups were statistically significant. Also, it is important to note that the differences between PRDX-1 concentrations for both females and males in each group became smaller with increasing severity of depression. With regard to PRDX-3, statistically significant differences were also revealed between depressed males and females, and the controls when it comes to varying levels of depression severity. It is worth noting that the largest increase in the concentration of this chemokine was reported in the group of severely depressed females.

CONCLUSION In depression, the inflammatory process may be activated by immune system stimulation. Our results suggest a correlation between serum Peroxiredoxin-1, Peroxiredoxin-3 levels, and severity of psychopathological signs that occur in depression. REFERENCES [1] Palmfeldt, J., Henningsen, K., Eriksen, S.A., Müller, H.K., Wiborg, O., 2016. Protein biomarkers of susceptibility and resilience to stress in a rat model of depression. Mol Cell Neurosci., 74, 87–95. [2] Poole, L.B., Nelson, K.J., 2016. Distribution and Features of the Six Classes of Peroxiredoxins. Mol Cells, 39(1), 53–59. [3] Salim, S., 2017. Oxidative Stress and the Central Nervous System. J Pharmacol Exp Ther., 360(1), 201–205.

Authors declare no conflict of interest